Equillium (EQ) Share-based Compensation (2018 - 2026)
Equillium (EQ) reported Share-based Compensation of $930000.0 for Q1 2026, up 49.76% year-over-year from $621000.0 in Q1 2025, and up 26.19% quarter-over-quarter from $737000.0 in Q4 2025.
Equillium (EQ) Share-based Compensation (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Share-based Compensation data on file, last reported at $930000.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $930000.0, up 49.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (down 22.59% YoY), and the FY2025 annual result was $2.3 million, down 38.08% from the prior year.
- Share-based Compensation improved to $930000.0 in Q1 2026 per EQ's latest filing, from $737000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.3 million in Q2 2022 and troughed at $401000.0 in Q3 2025.
- A 5-year average of $931764.7 and a median of $972000.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation plunged 60.1% in 2025, then jumped 49.76% in 2026.
- A 5-year view of Share-based Compensation shows it stood at $1.1 million in 2022, then dropped by 0.57% to $1.0 million in 2023, then fell by 21.51% to $821000.0 in 2024, then retreated by 10.23% to $737000.0 in 2025, then gained by 26.19% to $930000.0 in 2026.
- Business Quant data shows EQ's Share-based Compensation at $930000.0 in Q1 2026, $737000.0 in Q4 2025, and $401000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | 930,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 930,000.00 |
| Mar 31, 2026 | 930,000.00 |
| Dec 31, 2025 | 737,000.00 |
| Dec 31, 2025 | 737,000.00 |
| Sep 30, 2025 | 401,000.00 |
| Sep 30, 2025 | 401,000.00 |
| Jun 30, 2025 | 563,000.00 |
| Jun 30, 2025 | 563,000.00 |
| Mar 31, 2025 | 621,000.00 |
| Mar 31, 2025 | 621,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Dec 31, 2024 | 821,000.00 |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 952,000.00 |
| Jun 30, 2024 | 952,000.00 |
| Mar 31, 2024 | 972,000.00 |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2023 | 1.05 Mn |